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Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality. Although
docetaxel has recently been shown to extend the survival of patients with CRPC in two large randomised phase III studies,
subsequent treatment options remain limited for these patients. A greater understanding of the molecular causes of castration
resistance is allowing a more rational approach to the development of new drugs and many new agents are now in clinical
development. Therapeutic targets include the adrenal steroid synthesis pathway, androgen receptor signalling, the epidermal growth
factor receptor family, insulin growth factor-1 receptor, histone deacetylase, heat shock protein 90 and the tumour vasculature. Drugs
against these targets are giving an insight into the molecular pathogenesis of this disease and promise to improve patient quality of life
and survival. Finally, the recent discovery of chromosomal translocations resulting in the upregulation of one of at least 3 ETS genes
(ERG, ETV1, ETV4) may lead to novel agents for the treatment of this disease.
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Prostate cancer is the most common malignancy in western
societies and the second most common cause of male cancer-
related death in the UK (http://www.cancerresearchuk.org).
Despite the significant health burden of advanced prostate cancer,
the underlying biology of this disease is only now being unravelled.
A wealth of new laboratory data is fuelling rational, molecularly
targeted drug development programmes (Table 1) and some of the
challenges specific to the clinical study of this disease are being
overcome (Table 2). Furthermore, the recently described chromo-
somal rearrangement of ERG, ETV1 or ETV4, members of the ETS
family of oncogenes, repositioning adjacent to the androgen-
dependent promoter TMPRSS2 in up to 80% of prostate cancers, is
the first recurrent translocation described in a common solid
epithelial tumour and has been proposed to be a key process in
prostate carcinogenesis (Tomlins et al, 2005). The prevalence of
this genomic change and the potential therapeutic value of
targeting its transcriptional products are as yet unconfirmed.
However, the molecular biology of castration resistance is being
elucidated and this is now resulting in hypothesis-testing clinical
trials in patients with this disease. It is envisaged that this will have
a significant impact on the limited efficacy of treatments currently
available for patients with castration-resistant prostate cancer
(CRPC).
CURRENT TREATMENTS
Activation of the androgen receptor (AR) regulates transcription
of a diverse range of target genes involved in prostate cell
proliferation, differentiation and apoptosis. Drugs that reduce
circulating levels of androgens or that competitively inhibit the
action of androgen at the AR (antiandrogens) remain central to the
treatment of prostate cancer. Gonadotrophin-releasing hormone
(GnRH) agonists, such as goserelin and leuprorelin, inhibit
luteinising hormone (LH) secretion and suppress testicular
testosterone generation (medical castration). However, the dura-
tion of response to castration is short (12–33 months) and in
almost all patients, is followed by the emergence of a castration-
resistant phenotype (also referred to as hormone refractory,
HRPC). Antiandrogens (e.g. bicalutamide or flutamide) can be
used in combination with GnRH agonists to achieve ‘maximum
androgen blockade’. However, although low levels of androgens
remaining after castration are thought to play a role in the onset of
CRPC, this combination strategy has not proven to prolong
survival. In addition, up to 30% of patients experience a drop in
prostate specific antigen (PSA) after discontinuing antiandrogens
(Small et al, 2004), explained in part by the development of AR
gene mutations, or gene amplification and increased AR expres-
sion that may cause AR antagonists to behave as agonists (Chen
et al, 2004). Continuous low dose, oral glucocorticoids can also
result in temporary PSA responses in approximately 25% of
patients, presumably due to adrenal androgen suppression
(Berthold et al, 2005) (Figure 1). High doses of oestrogens can
also modulate AR function and clinical studies have confirmed
antitumour activity in CRPC. However, as a result of their
unfavourable toxicity profile, oestrogens are generally deferred to
fourth-line hormonal therapy (Figure 1). Diethylstilboestrol (DES)
is currently being investigated in combination with docetaxel after
the observation that it suppresses taxane-resistant b-tubulin
isotypes. In vitro, this has been shown to accentuate G2/M arrest
in prostate cancer cell lines by an oestrogen-receptor independent
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(Montgomery et al, 2005).
Treatment with docetaxel 75mgm
 2 and daily 10mg predniso-
lone has been shown to confer a survival advantage of a median of
2.5 months and improve quality of life in patients with CRPC when
compared to mitoxantrone and is now regarded as the standard of
care in patients for whom chemotherapy is indicated (Tannock
et al, 2004). Platinum containing regimens such as epirubicin,
carboplatin and 5-flurouracil have also shown antitumour activity
in phase II studies (Birtle et al, 2004) and their activity in patients
who fail docetaxel treatment is undergoing evaluation. Satraplatin
(JM-216), an oral platinum compound, is currently being evaluated
in a large international trial (SPARC), in combination with
prednisolone as second-line treatment after docetaxel. Novel
tubulin binding drugs such as the epothilone B analogue,
ixabepilone (BMS-247550)(Galsky et al, 2005) and the halichon-
drin B analogue, E7389 (Kuznetsov et al, 2004), have demonstrated
promise in the post-docetaxel setting and clinical trials are
ongoing.
The major impact on the quality of life of most patients with
CRPC occurs as a result of their disease metastasising to bone.
Single fraction palliative radiotherapy can be used to control pain
from solitary sites of disease. The use of bisphosphonates, such as
zoledronic acid, remains controversial and although one study
suggests a reduction in skeletal-related complications, overall no
improvement in patient quality of life or survival has been
reported (Saad et al, 2004). For patients with widespread painful
bone involvement, treatment with bone-seeking radiopharmaceu-
ticals, for example strontium-89, is available in specialist centres
and offers a targeted approach for providing rapid pain relief. The
less myelosuppressive radioisotope, the a-emitter radium 223, is
also currently in phase II studies, and may be superior to
strontium as administration of higher doses is not as limited by
marrow toxicity (Nilsson et al, 2005).
WHY CURRENT THERAPIES FAIL: MOLECULAR
MECHANISMS CAUSING CASTRATION RESISTANCE
The restricted therapeutic options available to prostate cancer
patients when hormonal therapy fails underscores the urgent need
for the development of novel agents to tackle the castration
refractory state. The key to drug development lies in identifying
and characterising targets and pathways driving cancer growth in
this disease. As prostate cancer progresses, prostate cancer cells
evolve, developing mechanisms to survive in an androgen-depleted
environment. Postulated and documented resistance mechanisms
are discussed below and in Figure 2.
Table 1 Factors specific to advanced prostate cancer that make the development of new treatments challenging
Challenge Solution
1. Preclinical models are not representative of clinical behaviour of disease Generation of new cell lines and novel tumour models, particularly models with
TMPRSS2/ETS gene translocations
2. Metastatic castration resistant tissue is difficult to access (many patients have
solely bone or inaccessible intra-abdominal metastasis)
Recruitment of patients to research projects involving tumour tissue acquisition
3. Biology underlying CRPC is not well defined Increased funding of research in CRPC and interest among the scientific community
and translational researchers
4. No measurable disease in most patients and inadequate surrogates of clinical
benefit limit utility of small nonrandomised studies
Evaluation and establishment of new surrogate markers, for example, enumeration
of circulating tumour cells, PET imaging
CRPC, castration resistant prostate cancer; PET, positron emission tomography.
Table 2 New drugs under investigation for the treatment of CRPC
Target Biological effect Drug Stage of clinical development
17a hydroxylase/C17, 20 lyase Suppression of adrenal androgen precursors Abiraterone acetate Phase I/II
HSP90 Inhibition of AR signalling 17-AAG Phase II
17-DMAG Phase I
HDAC Downregulation of AR SAHA Phase II
FK228 Phase II
Vitamin D receptor Agonism of VDR antiproliferative effects DN-101 Phase III
EB1089 Phase I
PI3 kinase Inhibit PI3K signalling axis P1-103
ZSTK474
Phase I trials anticipated to start in 2006
mTOR Inhibition of mTOR-dependent protein translation CCI-779 Phase II
RAD001 Phase II
IGF1-R Inhibit IGF1-R signalling axis CP-751, 851 Phase I
Phase II trials anticipated to start 2006
ErbB receptor family Inhibit erbB signalling axis Gefitinib Negative phase II trials
Pertuzumab (2C4) Negative phase II trials
Survivin Proapoptotic YM-155 Phase II
BCl-2 Proapoptotic G3139 Phase II
VEGF Antiangiogenesis Bevacizumab Phase III
VEGFR Antiangiogenesis BAY 43-9006 Phase II
AZD2171 Phase I/II
ETA Inhibition of endothelin-1 axis Atrasentan Phase III trials (first trial did not meet its end point)
b-Tubulin Cell-cycle arrest Ixabepilone Phase II/Phase III
E7389
HSP, heat shock protein; AR, androgen receptor; 17-AAG, 17- allylamino-17-demethoxygeldanamycin; 17-DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamycin;
HDAC, histone deacetylase; SAHA, suberoylanilide hydroxyamic acid; PI3K, phosphatidylinositol-3-kinase; mTOR, mammalian target of rapamycin; IGF1-R, insulin growth factor
receptor; VEGF (R), vascular endothelial growth factor (receptor); ETA, endothelin-A.
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Continued (androgen-dependent) PSA secretion and the presence
in tumour samples of androgens and AR mRNA expression at
levels associated with active AR signalling strongly suggest that
reactivation of the AR and AR-responsive pathways is one
mechanism by which tumours become resistant to androgen
deprivation (Titus et al, 2005). The peripheral conversion of
adrenal androgenic steroids (primarily androstenedione) to
testosterone by 17-ketoreductase could account for these intra-
tumoural androgens although it has been hypothesised that altered
regulation of tumour enzymes involved in the synthesis and
inactivation of androgens may be one cause for their accumula-
tion.
Prostate cancer cells also circumvent the effects of androgen
blockade, by developing the ability to use very low levels of
androgen to grow. DNA amplification resulting in increased AR
expression can result in a receptor capable of activation with low
levels of ligand, further supporting AR signalling as a mechanism
for castration resistance. In isogenic cell lines, increased expres-
sion of AR mRNA by less than two-fold results in resistance to
antiandrogens (Chen et al, 2004).
There is therefore increasing evidence that a role may exist for
novel strategies to target the AR and inhibit androgen synthesis,
with the aim of creating an androgen-free environment in prostate
tumours. Alternative therapeutic targets relating to the AR include
heat shock proteins (HSP) and histone deacetylases (HDAC) whose
role is in maintaining the function and stability of the AR.
AR gene mutations and altered ligand specificity
While androgens are pivotal for the growth of CRPC, mutations in
the AR lead to its activation by nonandrogenic steroid molecules
and antiandrogens (Figure 2). The majority of AR mutations found
in this disease are located at the ligand-binding domain. These
occur more frequently in CRPC, and may, in part, explain why 10–
30% of patients receiving antiandrogens experience a paradoxical
PSA drop on cessation of treatment (Small et al, 2004).
Downstream signalling of the AR
A number of signal transduction processes have been implicated in
activation of downstream AR signalling that is independent of
ligand binding to the AR. These include the epidermal growth
factor receptor family, the insulin growth factor-1 receptor, and
the phosphoinositide 3-kinase pathway (Figure 2).
Bypass pathways
One of the most important mechanisms in the development of
CRPC is the induction of a bypass pathway independent of the AR
that can overcome apoptosis induced by androgen depletion.
By bypassing the AR completely, prostate cancer cells survive
independent of ligand-mediated or nonligand-mediated AR
activation (Figure 2). One such example of this is the upregulation
of antiapoptotic proteins, including bcl-2 or survivin.
Stem cells
Prostate cancer stem cells (PCSC) are rare, undifferentiated cells
that do not express the AR and are not dependent on androgens
for survival. Prostate cancer stem cells are thought to be
responsible for maintaining the tumour and as they are able to
survive androgen deprivation therapy (ADT), they could result in
relapse with castration-resistant disease several months to years
after an initial response. PCSC have been isolated from tumour
samples based on high surface expression of integrin a2b1 and
CD133 and are being screened for unique characteristics that will
allow their selective targeting with novel therapeutic agents
(Collins et al, 2005).
OPTIMISING THE SUCCESSFUL DEVELOPMENT OF
AGENTS FOR CRPC
With our increasing understanding of the genes and pathways that
drive CRPC, therapeutic agents can be developed that act on the
molecular targets defined by the key genetic and molecular
Clinical  scenario Standard treatments Alternative  options
Rising PSA/clinical or
radiological progression in
castrate patient
Addition of antiandrogen
Rising PSA in the absence
of symptoms
 Third-line hormone therapy:
dexamethasone 0.5 mg daily
Clinical trial of targeted therapy−
low toxicity
Clinical trial of targeted therapy−
potentially low toxicity
Rising PSA in the absence
of symptoms
Fourth-line hormone therapy:
diethylystilboestrol 1 or 3 mg
daily Ketoconazole 400 mg t.d.s.−
US practice
Rising PSA  or symptoms
from metastatic disease
Docetaxel 75 mg m−2 3 weekly Clinical trial of docetaxel in 
combination with novel
targeted agent
Taxane-resistant disease
Mitoxantrone 12 mg m−2 3 weekly
    plus 10 mg prednisolone daily
Clinical trial of novel cytotoxic
and/or targeted therapy
Figure 1 Treatment flow chart for patients diagnosed with CRPC.
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becoming increasingly available for CRPC, it is critical that the
drug development process is optimised to ensure the cost and
length of time required for the approval of successful drugs is
reduced. Critical to this process is the use of pharmacokinetic (PK)
and pharmacodynamic (PD) end points, allowing a pharmacolo-
gical ‘audit trail’ to be constructed. PK end points provide
information on how much drug enters the body, and ideally into
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Figure 2 Novel therapeutic targets and proposed mechanisms of androgen resistance (text in red) in hormone refractory prostate cancer. (1)
Hypersensitive Pathway: AR amplification, increased AR expression or alterations in corepressor/coactivator function. (2) Versatile receptor: mutations in the
ligand-binding domain of the AR permitting nonandrogenic ligand binding. (3) Alternative routes: utilisation of AR machinery by alternative pathways, that is,
PI3K/Akt. (4) Bypass pathways: bypassing of the AR and its cellular machinery entirely, that is, upregulation of the antiapoptotic protein Bcl-2. Therapeutic
targets include: the adrenal steroid synthesis pathway, AR signalling, growth factor receptors (GFR), PTEN (phosphatase and tensin homolog) and PI3K
(phosphatidylinositide 3-OH kinase) signalling, angiogenesis and apoptosis. HSP90 denotes heat shock protein 90; PIP2 phosphatidylinositol-4,5-
bisphosphate; PIP3 phosphatidylinositol-3,4,5- triphosphate; Akt protein kinase B; mTOR mammalian target of rapamycin; oncogenes Ras, Raf, Mek, Erk; Bcl-2
antiapoptotic protein; APAF1 apoptotic peptidase activating factor 1; IAP inhibitor of apoptosis family (of which survivin is a member). Solid lines indicate
promotion. Broken lines indicate inhibition.
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does with respect to modulation of the molecular target and
biochemical pathway, and whether this translates into achieving
the desired biological effect (e.g. apoptosis). This ensures that all of
the key stages in prostate cancer drug development – from
preclinical models testing and drug administration in patients,
through to the biological effect and the clinical outcome – can be
monitored and interpreted (Workman, 2003). The audit trail thus
provides a basis for answering critical questions in a rational,
hypothesis-driven fashion and ensures that the drug development
process is scientific and rigorous. In CRPC this is complicated by
the inaccessibility of primary and metastatic tumour (solely bone
metastasis in most patients), and by the lack of technology for
assessing response to drugs (no measurable visceral disease by CT/
MRI, and inadequacy of PSA assay) (see Table 2 and Ongoing
Challenges).
TARGETING AR SIGNALLING
Inhibition of the steroid synthesis pathway
Ketoconazole, an azole antifungal agent that weakly inhibits
several cytochrome P450 enzymes involved in adrenal steroid
synthesis has been utilised to treat CRPC. Twenty to 35% of
patients who progress on antiandrogens have a short-lived PSA
response to ketoconazole and on progression postresponse have a
significant rise in plasma adrenal androgens (Small et al, 2004)
suggesting that this may be related to ketoconazole resistance.
A more specific inhibitor of androgen synthesis is currently in
clinical development. Abiraterone acetate (AA) is a potent, orally
bioavailable and irreversible inhibitor of 17a-hydroxylase/C17,
20-lyase: a key enzyme involved in the 17-hydroxylation of
pregnenolone and progesterone and their subsequent conversion
to the adrenal androgens, dehydroepiandrosterone (DHEA) and
androstenedione. Its inhibition causes a reduction in testosterone
levels (O’Donnell et al, 2004). A series of three phase I trials
investigating the ability of AA to cause maximum suppression of
testosterone synthesis when given to castrate and noncastrate
males with prostate cancer has been conducted (O’Donnell et al,
2004). Abiraterone acetate, administered as a single dose to
castrate males, achieved significant further suppression of
testosterone and androstenedione that lasted from 2 to 5 days.
In these phase I studies, AA was well tolerated and although there
was no clinical or biochemical evidence of glucocorticoid
deficiency, a reduced cortisol response to ACTH stimulation after
12 days continuous AA dosing was reported, in keeping with a
reduction in adrenocortical reserve. Continuous, daily AA is
currently being studied in castrate CRPC patients who have failed
GnRH agonists. Although sufferers of familial 17a-hydroxylase
deficiency do not develop adrenocortical deficiency, patients on
continuous AA may require glucocorticoid rescue. Drugs targeting
steroidogenesis, the aromatase inhibitors, have been successfully
used in the treatment of breast cancer and AA may impact the
management of CRPC in a similar fashion.
Ablation of intracellular AR signalling
Heat shock protein 90 is a member of the family of heat shock
proteins that acts as an ATP-ase driven molecular chaperone. Heat
shock proteins90 is required for the stability, conformation,
function and regulation of a number of key oncogenic ‘client
proteins’, including ErbB2 and AKT, as well as several transcrip-
tion factors including AR (Chen et al, 2005). In prostate cancer
animal models, the first-in-class HSP90 inhibitor 17-allylamino-
geldanamycin (17-AAG) causes the degradation of these client
proteins at nontoxic doses and inhibits the growth of hormone-
naive and castration-resistant tumours (Solit et al, 2003). 17-
allylaminogeldanamycin induced cell-cycle arrest and apotosis in
vitro and in vivo, and phase I trials have now been completed
(Banerji et al, 2005). These studies provided the proof-of-concept
for HSP90 inhibition at tolerable doses, as measured by changes in
client protein and HSP expression in peripheral blood lymphocytes
as well as tumour tissue of treated patients.
Histone deacetylase inhibitors can also inactivate the HSP90
chaperone and hence can deplete key client proteins such as AR.
LAQ824 and SAHA have demonstrated activity in preclinical
models, with depletion of AR through HSP90 inactivation (Chen
et al, 2005). Recently, aberrations of ‘global’ histone modification
have been observed in prostate cancer. Global levels of the
acetylation or methylation of five different residues in histones H3
and H4 were examined in prostate tumour samples; these histone
modification patterns can predict tumour grade and recurrence
(Seligson et al, 2005). Phase II trials of HDAC inhibitors are now
underway in CRPC, and interim results of FK228, a depsipeptide
that inhibits HDAC, were presented at ASCO 2006 by Molife et al
(abstract 217) and suggest clinically relevant antitumour activity.
TARGETING THE VITAMIN D RECEPTOR
Calcitriol (1,25-dihydroxycholecalciferol), the principal active
metabolite of vitamin D, demonstrates significant antineoplastic
activity in preclinical models of prostate cancer. The vitamin D
receptor, a member of the nuclear steroid hormone receptor
superfamily, mediates transcriptional activation of cyclin-depen-
dent kinase inhibitors causing G0/G1 cell-cycle arrest. Calcitriol
also modulates growth factor signalling, induces apoptosis through
downregulation of the antiapoptotic protein Bcl-2 and is
antiangiogenic (Beer et al, 2005). The concentration of calcitriol
required for antineoplastic activity in vitro far exceeds the normal
physiologic range and daily dosing is not achievable owing to
hypercalcaemia and hypercalcuria. Intermittent oral administra-
tion of calcitriol has been established as a means of achieving
potentially therapeutic peak concentrations. Interim results from
the double-blind randomised trial of docetaxel with or without
calcitriol (DN-101) (ASCENT) were presented at ASCO 2005 by
Beer et al (Abstract 4516). Patients received weekly docetaxel for 3
weeks of a 4-week cycle and either oral DN-101 or placebo. At a
median of 18 months follow-up, survival data from 250 patients
favours DN-101 (23.5 months) over placebo (16.4 months)
(P¼0.035; HR¼0.67). Low calcaemic vitamin D analogues, such
as seocalcitol (EB1089), have demonstrated antiproliferative effects
in preclinical models and may allow improved dose delivery and
antitumour activity.
TARGETING SIGNALLING IN CRPC
The development of agents to target specific upstream genes and
proteins potentially deregulated in prostate cancer also provides
an opportunity for anticancer therapy for CRPC. A number of
potential therapeutic targets have been elucidated for CRPC. The
most common genetic alteration in CRPC is probably loss of the
PTEN tumour-suppressor gene. In addition, profiling studies have
implicated a number of receptor tyrosine kinases as being
overexpressed in differing stages of prostate cancer, including
the erbB kinase family (ErbB1 (epidermal growth factor receptor,
(EGFR)), ErbB2 (HER2/neu), and ErbB3 (HER3)), the insulin-like
growth factor receptor (IGF-1R), and the platelet-derived growth
factor receptor (PDGF-R).
PTEN and phosphoinositide 3-kinase signalling
The phosphoinositide 3-kinase (PI3K) pathway regulates many
key cellular processes. There is now overwhelming evidence
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malignant progression of prostate cancer. Functional loss of PTEN
(which is the negative regulator of PI3K) is thought to occur in up
to half of all prostate cancers, and is associated with increased
activation of AKT and the downstream kinase mTOR, which is
involved in regulating protein synthesis. Loss of PTEN and
increased AKT-1 phosphorylation is typically associated with
higher Gleason grading, advanced stage and poorer prognosis
(Ayala et al, 2004). The PI3K pathway appears to be critical in the
development of CRPC: in vitro data suggest that overexpression
and activation of AKT can trigger prostate cancer androgen escape
via altered sensitivity and activation of AR (Edwards and Bartlett,
2005).
The PI3K pathway therefore presents a number of attractive
kinase targets for drug development. The first generation of PI3K
inhibitors were limited by lack of potency, poor selectivity for the
oncogenic class I PI3K isoforms, and unsuitable pharmaceutical
properties. Newer generation inhibitors have improved pharma-
cologic properties, appear highly selective and have demonstrated
growth inhibition in vitro and in vivo; a number of these inhibitors
are shortly to enter the clinic (Hennessy et al, 2005). Preliminary
data from these inhibitors show that the likely molecular response
is G1/S phase arrest, with no significant apoptosis; PI3K inhibitors
may therefore be best used in combination with inhibitors of other
survival signalling pathways, for example, EGFR/MEK/MAPK (She
et al, 2005) or following treatment with cytotoxics. Similarly, a
number of specific small molecule inhibitors of AKT are in
development and should enter clinical trials shortly. Proof of
principle that the PI3K pathway can be successfully targeted for
clinical use in cancer has been demonstrated by the development
of rapamycin analogues (CCI-779, RAD-001) that inhibit the
mTOR kinase and are now undergoing evaluation in phase II trials
in CRPC. RAD-001 has been shown to completely reverse the
prostate intraepithelial neoplasia (PIN) phenotype in murine
transgenic AKT models; in addition mTOR-dependent regulation
of HIF-1a may produce an antiangiogenic effect (Majumder et al,
2004). One of the main concerns regarding the use of mTOR
inhibitors is the possibility of ‘negative feedback’ with activation of
upstream targets such as IGF-1R and p-AKT (O’Reilly et al, 2006).
IGF-1R signalling
Activation of IGF-1R by IGF-1 or IGF-2 results in phosphorylation
and membrane recruitment of insulin receptor substrate (IRS)
proteins and activation of intracellular signalling pathways,
including PI3K and MAPK. The activated receptor is thus able to
induce AR signalling in the absence of AR ligand activation. IGF-
1R expression has been reported to alter as prostate cells progress
from a normal to a malignant phenotype and IGF-1R is implicated
in resistance to therapy (Pollak et al, 2004). Targeting of IGF-1R
signalling in preclinical tumour models has suppressed growth of
prostate cancer cells, induced apoptosis in vitro and in vivo and
has sensitised cancer cells to conventional chemotherapeutic
treatment and irradiation (Burtrum et al, 2003). An IGF-1R
targeting monoclonal antibody is now being evaluated for the
treatment of CRPC.
ErbB receptors
A number of studies suggest that crosstalk between the activated
ErbB receptor kinase axis and the AR receptor signalling pathway
may be important for the growth and survival of both hormone-
sensitive and CRPC. Epidermal growth factor receptor expression
correlates with Gleason score and disease progression and has
been implicated in the progression to castration resistance (Di
Lorenzo et al, 2002). Signalling mediated through ErbB2/ErbB3 is
implicated in AR activation through effects on AR DNA binding
and stability (Mellinghoff et al, 2004). However, phase II studies of
single agent ErbB signalling pathway inhibitors, including gefitinib
(a small molecule EGFR tyrosine kinase inhibitor), trastuzumab (a
monoclonal antibody to HER2) and pertuzumab (a HER2
dimerisation inhibitor) have reported no clinically significant
activity in unselected CRPC patients (Ziada et al, 2004; Canil et al,
2005; de Bono et al, 2005).
OTHER STRATEGIES
One of the important mechanisms in the development of CRPC is
the induction of a bypass pathway independent of AR that can
overcome apoptosis induced by androgen depletion. Survivin is a
member of the inhibitor of apoptosis (IAP) family and is a
candidate gene that can block apoptosis. Survivin has been
associated with phenotypically aggressive prostate carcinoma and
with resistance to antiandrogen therapy (Zhang et al, 2005). Small
molecule inhibitors of survivin function have demonstrated
efficacy in preclinical prostate models, and are in phase I/II
clinical trials. Bcl-2 is another apoptosis inhibiting protein, and its
expression in CRPC correlates with a worse prognosis. In prostate
cancer models, Bcl-2 antisense oligonucleotides inhibited the
expression of Bcl-2, delayed the development of androgen
independence and enhanced the effects of chemotherapy. A phase
II study of the Bcl-2 antisense G3139 (oblimersen sodium) and
docetaxel has shown promising antitumour activity and phase III
trials are now ongoing (Tolcher et al, 2005).
An alternative strategy is targeting neovascularisation. Progres-
sion of prostate cancer has been associated with increased
angiogenesis, at least in part associated with upregulation of
proangiogenic factors, such as members of the VEGF family (Li
et al, 2005). Antiangiogenic agents can reduce intratumoural
interstitial pressure and increase anticancer drug delivery and
enhance radiotherapy efficacy (Jain R, Science 2005). Bevacizumab,
a humanised murine monoclonal antibody to VEGF, has resulted
in clinical benefit in a number of tumour types, including
colorectal, non-small-cell lung and breast cancer, and is currently
being evaluated in CRPC in a randomised double-blinded,
placebo-controlled phase III study administering docetaxel with
or without bevacizumab (CALGB 90401).
Endothelin-1, via the endothelin-A receptor, inhibits apoptosis,
stimulates proliferation of prostate cancer cells and osteoblasts and
induces neovascularisation in response to hypoxia, making this
effector pathway a promising therapeutic target. Atrasentan, a
selective oral ET-A receptor antagonist, has been tested in patients
with CRPC but its antitumour activity has been insufficient to
warrant regulatory approval for its inclusion in the treatment of
advanced CRPC with bone metastasis (Carducci et al, 2003). Phase
III data from the treatment of patients with earlier stage disease
treated with atrasentan is awaited.
ONGOING CHALLENGES
It is envisioned that the next decade will result in significant
changes in the treatment of prostate cancer (Table 2). A key
challenge that remains to be addressed is the identification of
suitable surrogate end points for survival. Prostate specific antigen
does not predict survival and therefore, is not suitable for
evaluating response to drugs. Recently, the rate of rise of PSA
(PSA velocity) has been associated with the length of survival after
treatment and may prove to be a suitable surrogate for survival
(Rozhansky et al, 2006). However, PSA secretion is driven by AR
signalling and agents that directly target AR signalling could be
ineffective treatments yet modulate PSA levels. New technology
allows the isolation and enumeration of circulating tumour cells
(CTC) in patients with advanced prostate cancer. The number of
CTC pre- and post-chemotherapy above and below a set threshold
has proved to be a true surrogate marker for response and survival
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currently ongoing investigating this technology in prostate cancer.
Diffusion-weighted magnetic resonance imaging and positron
emission scans using
18F-fluoro-2-deoxy-D-glucose or FLT
18F-
fluoro-30deoxy-30-L-fluorothymidine may also be valuable tools to
assess CRPC and may allow early assessment of disease response.
These surrogates could become primary end points in efficacy
trials expediting future advances and drug approval.
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